Specify a stock or a cryptocurrency in the search bar to get a summary
Appili Therapeutics Inc
APLIFAppili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada. Address: #21-1344 Summer Street, Halifax, NS, Canada, B3H 0A8
Analytics
WallStreet Target Price
0.21 CADP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures APLIF
Dividend Analytics APLIF
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History APLIF
Stock Valuation APLIF
Financials APLIF
Results | 2019 | Dynamics |